Press release -
Chikungunya - Pipeline Review, H2 2015
ChikungunyaPipeline Review, H2 2015, provides an overview of the Chikungunyas therapeutic pipeline.
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chikungunya Overview 9
Therapeutics Development 10
Pipeline Products for Chikungunya - Overview 10
Pipeline Products for Chikungunya - Comparative Analysis 11
Chikungunya - Therapeutics under Development by Companies 12
Chikungunya - Therapeutics under Investigation by Universities/Institutes 15
Chikungunya - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Chikungunya - Products under Development by Companies 19
Chikungunya - Products under Investigation by Universities/Institutes 21
Chikungunya - Companies Involved in Therapeutics Development 22
Abivax S.A. 22
Arbovax, Inc. 23
Arno Therapeutics, Inc. 24
Bharat Biotech International Limited 25
Etubics Corporation 26
Indian Immunologicals Limited 27
Inovio Pharmaceuticals, Inc. 28
Integral Molecular, Inc. 29
Merck & Co., Inc. 30
Nanotherapeutics, Inc. 31
PaxVax 32
Profectus BioSciences, Inc. 33
Takeda Pharmaceutical Company Limited 34
Themis Bioscience GmbH 35
Chikungunya - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ABX-309 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Antibody for Chikungunya - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AR-12 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chikungunya vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chikungunya vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chikungunya vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
chikungunya vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
chikungunya vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chikungunya vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
chikungunya vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
chikungunya vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
chikungunya vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
chikungunya vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
chikungunya vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chikungunya vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
chikungunya vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
chikungunya vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
chikungunya vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
chikungunya vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
DEF-201 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IMCKV-063 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibodies for Chikungunya - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MV-CHIK - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chikungunya - Recent Pipeline Updates 75
Chikungunya - Dormant Projects 78
Chikungunya - Product Development Milestones 79
Featured News & Press Releases 79
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 79
Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 80
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 81
Nov 20, 2014: Themis Bioscience’s Vaccine Against Chikunguya Successful In Phase 1 82
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 83
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 83
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 84
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 84
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List Of Tables
Number of Products under Development for Chikungunya, H2 2015 10
Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Development by Companies, H2 2015 (Contd...1) 14
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd...1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Chikungunya - Pipeline by Abivax S.A., H2 2015 22
Chikungunya - Pipeline by Arbovax, Inc., H2 2015 23
Chikungunya - Pipeline by Arno Therapeutics, Inc., H2 2015 24
Chikungunya - Pipeline by Bharat Biotech International Limited, H2 2015 25
Chikungunya - Pipeline by Etubics Corporation, H2 2015 26
Chikungunya - Pipeline by Indian Immunologicals Limited, H2 2015 27
Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 28
Chikungunya - Pipeline by Integral Molecular, Inc., H2 2015 29
Chikungunya - Pipeline by Merck & Co., Inc., H2 2015 30
Chikungunya - Pipeline by Nanotherapeutics, Inc., H2 2015 31
Chikungunya - Pipeline by PaxVax, H2 2015 32
Chikungunya - Pipeline by Profectus BioSciences, Inc., H2 2015 33
Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 34
Chikungunya - Pipeline by Themis Bioscience GmbH, H2 2015 35
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Stage and Target, H2 2015 38
Number of Products by Stage and Mechanism of Action, H2 2015 40
Number of Products by Stage and Route of Administration, H2 2015 42
Number of Products by Stage and Molecule Type, H2 2015 44
Chikungunya Therapeutics - Recent Pipeline Updates, H2 2015 75
Chikungunya - Dormant Projects, H2 2015 78
List Of Figures
Number of Products under Development for Chikungunya, H2 2015 10
Number of Products under Development for Chikungunya - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 36
Number of Products by Top 10 Targets, H2 2015 37
Number of Products by Stage and Top 10 Targets, H2 2015 37
Number of Products by Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39
Number of Products by Routes of Administration, H2 2015 41
Number of Products by Stage and Routes of Administration, H2 2015 41
Number of Products by Top 10 Molecule Types, H2 2015 43
Number of Products by Stage and Top 10 Molecule Types, H2 2015 43
Topics
- Health Care, Health Service
Categories
- chikungunya market
- chikungunya
- global chikungunya market
- chikungunya market strategy
- chikungunya market application
- chikungunya market segmentation
- chikungunya market technology
- global chikungunya
- chikungunya market size
- chikungunya market share
- chikungunya market trends
- chikungunya market forecast
- chikungunya market futures
- chikungunya market opportunities
- chikungunya market news
- chikungunya market research
- chikungunya market growth
- chikungunya market analysis
- chikungunya market developments
- chikungunya market overview
- chikungunya market outlook
- chikungunya market demands
About Us:
With the arsenal of different search reports, Research Beam helps you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.
With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.
Contact Us:
Deep Joshi
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
U.S. & Canada Toll Free: + 1-800-910-6452
International: + 1-503-894-6022
UK: + 44-845-528-1300
India: +91 20 66346070
Fax : +1 (855) 550-5975
Email: help@researchbeam.com
Web: http://www.researchbeam.com/
Allied Analytics LLP